<DOC>
	<DOCNO>NCT01014624</DOCNO>
	<brief_summary>The primary objective study describe cumulative proportion subject return baseline platelet P2Y12 receptor function time ( 12 day post last maintenance dose ) follow discontinuation prasugrel 10 mg daily x 7 day assess Accumetrics VerifyNow P2Y12 reaction unit ( PRU ) describe Kaplan Meier curve . The primary analysis descriptive intend provide information relate return baseline platelet function follow discontinuation maintenance therapy either prasugrel clopidogrel .</brief_summary>
	<brief_title>Prasugrel/Clopidogrel Maintenance Dose Washout Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Male female subject &gt; /= 18 year &lt; 75 year age Weight &gt; /= 60 kg On aspirin therapy ( 81 mg 325 mg daily ) time screen able maintain consistent aspirin dose regimen baseline visit final study visit Subjects contraindication thienopyridine ( ie , prasugrel , clopidogrel ticlopidine ) , history stable atherosclerosis represent Coronary Artery disease , define follow : chronic stable angina Prior history acute coronary syndrome ( &gt; /= 30 day screen ) include unstable angina acute myocardial infarction ( ST elevation MI [ STEMI ] nonST elevation MI [ NSTEMI ] ) , currently prescribe currently thienopyridine therapy ; Previous coronary revascularization include percutaneous transluminal coronary angioplasty ( PTCA ) , stent , coronary artery bypass grafting ( CABG ) coronary artery disease ( &gt; /= 50 % obstruction ) least one coronary vessel angiography Female subject meet one follow : Women childbearing potential negative serum pregnancy test screen breast feeding , plan become pregnant study , agree use approve method birth control study . Approved method birth control oral , path , injectable implantable hormonal contraception , intrauterine device , diaphragm plus spermicide , female condom plus spermicide . Abstinence , partner 's use condom , partner 's vasectomy NOT acceptable method contraception . Women postmenopausal least 1 year hysterectomy , bilateral salpingooophorectomy , tubal ligation least 6 month prior sign inform consent form . Subjects competent mental condition provide write informed consent enter study . Any formal indication use thienopyridine . Subjects history refractory ventricular arrhythmia . Subjects history implantable defibrillator device . Subjects history evidence congestive heart failure ( New York Heart Association [ NYHA ] Class III ) within 6 month prior screen . Subjects significant hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg ) either time screen baseline assessment . Bleeding Risk Any known contraindication treatment anticoagulant antiplatelet agent Prior history clinical suspicion cerebral vascular malformation , intracranial tumor , transient ischemic attack ( TIA ) , stroke , recent history ( within 3 month ) head trauma Prior history presence significant bleeding disorder ( eg , hematemesis , melena , severe recurrent epistaxis , hemoptysis , hematuria , intraocular bleeding ) History ( within last 5 year ) presence gastric ulcer . Previous history duodenal ulcer acceptable must successfully surgically medically treated evidence disease past 6 month ( screen ) . Prior history abnormal bleeding tendency ( ie , prolonged bleeding dental extraction , tonsillectomy , previous surgical procedure ) Known prior history thrombocytopenia ( platelet count &lt; 100,000/mm³ ) thrombocytosis ( platelet count &gt; 500,000/mm³ ) recent history ( within six month ) hemoglobin &lt; 10 mg/dL Clinically significant range value prothrombin time , activate partial thromboplastin time ( aPTT ) , platelet count , hemoglobin screening , investigator 's opinion History major surgery , severe trauma , fracture , organ biopsy within 3 month prior enrollment Prior/Concomitant Therapy Subjects take prasugrel , clopidogrel , ticlopidine , cilostazol , dipyridamole , warfarin , heparin , direct thrombin inhibitor , glycoprotein IIB/IIIa inhibitor =10 day prior screen study participation The use ( plan use ) fibrinolytic agent within 30 day screen study participation Subjects receive treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor exceed 3 dos per week Subjects receive proton pump inhibitor ( PPIs ) , eg , ( lansoprazole , esomeprazole , omeprazole , pantoprazole , rabeprazole ) =10 day prior screen study participation General Investigator site personnel directly affiliate study immediate family investigator site personnel directly affiliate study . Immediate family define spouse , parent , child , sibling , whether biological legally adopt Daiichi Sankyo Eli Lilly employee Currently enrol , discontinue within last 30 day prior baseline , clinical study involve offlabel use investigational drug device , concurrently enrol nonobservational clinical study type medical research judge scientifically medically compatible study Have previously complete withdrawn study Women know pregnant and/or receive positive serum pregnancy test result , give birth within past 90 day , and/or breastfeeding Results clinical laboratory test time screen judge clinically significant subject , determine investigator Known allergy intolerance aspirin and/or thienopyridines ( prasugrel , clopidogrel , ticlopidine ) Evidence significant active neuropsychiatric disease , alcohol abuse drug abuse , investigator 's opinion Evidence active hepatic disease , follow ; positive human immunodeficiency virus ( HIV ) antibody , positive hepatitis C antibody , positive hepatitis B surface antigen ; serum alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , gammaglutamyltransferase ( GGT ) &gt; /= 3 time upper limit normal ( ULN ) laboratory reference range ; bilirubin &gt; /= 2 time ULN laboratory reference range screen Subjects unreliable unwilling make available duration study abide research unit policy procedure study restriction Subjects angiogram &lt; /= 7 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>thienopyridine</keyword>
	<keyword>pharmacologic action</keyword>
	<keyword>prasugrel</keyword>
	<keyword>clopidogrel</keyword>
</DOC>